Treatment with glucagon-like Peptide-1 agonist exendin-4 in a patient with hypothalamic obesity secondary to intracranial tumor.

Simmons JH, Shoemaker AH, Roth CL
Horm Res Paediatr. 2012 78 (1): 54-8

PMID: 22831918 · DOI:10.1159/000339469

BACKGROUND/AIMS - Patients with hypothalamic tumors frequently experience severe obesity, and its treatment with diet, exercise, and/or pharmacologic treatment has had limited effect. Glucagon-like peptide-1 agonist exenatide (exendin-4), used for treatment of type 2 diabetes, causes persistent weight loss via signaling in the brainstem.

METHODS - We report the case of a 17-year-old patient with obesity resulting from a hypothalamic germ cell tumor. He was treated by chemoradiotherapy and exenatide at a dose of 5 µg subcutaneously twice daily.

RESULTS - Exenatide resulted in a 29-kg weight loss (BMI reduction from 37.1 to 29.1) after 2.5 years of treatment; significant weight gain occurred shortly after exenatide was discontinued.

CONCLUSION - Exenatide resulted in considerable reduction of body weight in a patient with severe hypothalamic obesity. This novel observation requires follow-up clinical studies for establishing the effects of exenatide in patients with disrupted hypothalamic energy regulatory pathways.

Copyright © 2012 S. Karger AG, Basel.

MeSH Terms (12)

Adolescent Brain Neoplasms Exenatide Glucagon-Like Peptide 1 Humans Hypoglycemic Agents Hypothalamic Neoplasms Male Neoplasms, Germ Cell and Embryonal Obesity Peptides Venoms

Connections (1)

This publication is referenced by other Labnodes entities: